Thin Film Electronics ASA and smart systems announced a partnership with the Ypsomed Group (a developer and manufacturer of injection systems for self-medication.
Thin Film Electronics ASA and smart systems announced a partnership with the Ypsomed Group (a developer and manufacturer of injection systems for self-medication. These companies will collaborate to incorporate Thinfilm’s NFC OpenSense™ technology in the YpsoMate autoinjector as a means of improving patient self-care compliance. YpsoMate autoinjectors are disposable 2-step injection systems that house pre-filled glass or polymer syringes, and are triggered by push-on-skin activation. Patients use autoinjectors to self-deliver periodic injections for the ongoing management of chronic conditions such as rheumatoid arthritis or cardiovascular indications, making compliance a critical factor in their treatment plan. Through the combination of the NFC OpenSense tags and a custom mobile app, patients will be able to receive valuable compliance assistance such as adherence history, injection reminders, usage guidelines, refill instructions and authentication. In turn, doctors will be able to track whether or not patients are adhering to daily self-medication requirements. NFC OpenSense tags are thin, flexible labels that can detect both the state before and after injection of YpsoMate® Smart autoinjector, wirelessly deliver content to patients through the simple tap of a smartphone, and record patients’ interactions with the YpsoMate Smart device in the cloud. Each tag contains a unique identifier that makes it possible to track every YpsoMate Smart to the individual-item level. In addition, the tag remains active even after the factory seal has been broken, enabling an extended dialogue between patients, doctors and brands.